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Pre ´cis
For patients who undergo re-resection for recurrent extra abdominal desmoid tumor, and in whom microscopically or
grossly positive margins are found, the use of postoperative radiation is not only warranted, but is critical in the ability to
establish local control. We recommend total doses of at least 50 Gy for microscopic positive surgical margins and 56 Gy for
gross residual surgical margins. We recommend the use of external beam irradiation alone for patients who have involvement
in the hand and plantar regions, while in the remaining areas treatment using external beam irradiation, brachytherapy alone,
or a combination of external beam with brachytherapy may be utilized.
Abstract
Background: To define the efficacy of postoperative irradiation in patients with recurrent extra-abdominal desmoid tumors in
whom surgical intervention has resulted in microscopically or grossly positive surgical margins.
Methods: A retrospective analysis was performed on all patients referred to the department of radiation oncology at the
Detroit Medical Center with a diagnosis of recurrent extra-abdominal desmoid tumor. This analysis includes all patients
seen from 1 January 1990 through 31 December 1999. A total of 11 patients were treated to 13 sites. Ten had
microscopically positive margins and three had gross residual disease. Three patients were noted to have multifocal disease at
the time of initial representation. Local control, survival, follow-up, and subsequent development of new tumors are
measured from the last day of treatment with irradiation.
Results: Thirteen sites were treated. Seven patients had received chemotherapy/hormonal therapy prior to surgery and/or
irradiation. The most commonly used drug was tamoxifen (n¼6). The type of radiation delivered included external beam
irradiation alone (n¼3), combined external beam irradiation and brachytherapy (n¼4), brachytherapy alone (n¼3) and
252-Cf neutron brachytherapy alone (n¼3). Follow-up has ranged from 29 to 115 months (median¼76 months). Three
patients have failed locally at 17, 24 and 29 months. One of these was treated for gross residual disease. No patient has died
of tumor-related causes. Salvage at the failed sites was possible in twom of three with re-irradiation using external neutrons
and/or aggressive surgical intervention and systemic therapy. Complications were most often noted to include decrease range
in motion, especially in joint areas, and skin reactions which were normal in presentation. In one site there was development
soft tissue necrosis.
Conclusion: Based on our experience we recommend postoperative irradiation for all recurrent extra-abdominal desmoid
lesions with microscopically or grossly positive surgical margins. Furthermore, patients with recurrent desmoid tumors
involving the bony structures of the hand or feet are poor candidates for brachytherapy alone. For patients with extremity
lesions, brachytherapy may be a reasonable treatment option provided adequate margins around the tumor bed are covered.
The continued recommended use of irradiation in this group of patients is warranted.
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Introduction
Treatment decision for desmoid tumors following
surgical intervention continues to be controversial.
There is no clear indication as to which patients may
benefit from additional therapy following surgical
removal, as no randomized trial has ever been
completed. However, for patients with gross or
microscopic residual disease or for those who have
recurrence, regardless of margin status, the use of
irradiation appears to improve local control.
1–6
There have also been recent attempts to define
whether chemotherapy and/or hormonal therapy
might also play a role in the treatment of desmoid
tumors, although less than impressive results have
been reported.
7,8
The decision to recommend radiation must
be weighed against the knowledge that this is a
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malignancies may be result of intervention.
9 While
many reports have described the use of irradiation for
both intra- and extra-abdominal desmoid tumors,
few have directed analysis in an attempt to define the
role of postoperative irradiation in patients who were
treated for recurrent extra-abdominal desmoid
tumors in whom resection has resulted in either
gross or microscopic residual disease.
Our aim was to review the experience at our center
to determine whether justification could be made for
the routine use of postoperative irradiation in this
specific patient population, and to determine how
best to deliver the irradiation.
Methods and materials
All patients treated for recurrent desmoid tumor and
in whom re-resection resulted in either gross or
microscopically positive margin were retrospectively
reviewed. The review period was from 1 January
1990 through December 1999. A total of 11 patients
were identified. Time from initial therapy to diag-
nosis of recurrence ranged from 3 to 50 months
(median¼5 months). Size of relapse, measured by
the greatest dimension on imaging, ranged from 3 to
23cm. Thirteen sites were treated in these 11
patients. Time to failure and local control, complica-
tions and all the parameters evaluated relating to
time are calculated from the last day of radiation
treatment.
All patients had their pathological slides reviewed
by one of the authors (DPL). Tumor size, surgical
margins and other pathological information were
recorded. Patient demographics, and treatment
parameters were recorded from hospital charts,
including the age of diagnosis, sex, race, site and
size of lesion, dates of surgical procedures including
biopsies, the type of surgical procedures performed,
brachytherapy and/or external beam irradiation
doses, chemotherapy and complications. Patients
with multicentric disease were also identified.
Pathologically, margins were considered microscopi-
cally positive if tumor cells were within 3mm of the
inked margins, and grossly positive if the margin of
resection was positive.
There were 11 patients in whom 13 sites were
treated. There were nine females and two males.
Ages ranged from 13 to 66 years at the time of initial
presentation (median n¼27 years). Follow-up for all
patients has ranged from 29 to 115 months
(median¼60 months).
The initial site of presentation was as follows
below: lower extremity (n¼6), buttock (n¼2),
shoulder/trunk (n¼3), upper extremity (n¼2). All
patients presented with either microscopic residual
disease (n¼10) or gross residual disease (n¼3).
Radiation was initiated within 2 weeks of surgical
intervention on all patients.
Seven patients received chemotherapy/hormonal
therapy prior to re-resection and radiation.
Tamoxifen was the most commonly used agent
(n¼6). No patient had a tumor response to systemic
therapy.
Six patients received brachytherapy as a sole
method of irradiation. Each of these patients received
twice daily treatment utilizing high dose rate remote
afterloading iridium-192 (n¼3) or manually loaded
californium-252, a neutron-emitting brachytherapy
source available at the Detroit Medical Center. Four
patients received combination of brachytherapy and
external beam irradiation, with each brachytherapy
application being delivered twice daily followed by
once daily external beam irradiation using fraction
sizes of 180–200cGy. Three patients received
external beam irradiation alone. These received
once daily irradiation using 180–200cGy per frac-
tion. Total doses, including conversion of high-dose
rate brachytherapy to low-dose rate brachytherapy
and use of an RBE of 4.5 for the Cf-252 brachyther-
apy, ranged from 46 to 64Gy. There was no
identifiable departmental choice for each of the
treatment regimens.
Results
Ten of 13 sites maintained local control between 32
and 115 months (median n¼82 months). Each of
the three patients treated with external beam
irradiation alone, or in combination with brachy-
therapy, maintained the local control.
In those patients receiving only brachytherapy,
local failure has developed in three patients at 17, 24
and 29 months. Two of the three receiving Cf-252
brachytherapy failed. The first Cf-252 patient to fail
was treated for gross residual disease which was
encased around the major neurovascular bundles of
the upper extremity which, if resected, would have
resulted in a dysfunctional limb. This patient has
been salvaged with combined surgery and multi-
agent chemotherapy. This patient remains NED at
12 months. The second Cf-252 patient to fail had
tumor that intertwined in the bones of the foot. This
patient was salvaged with amputation. The third
failure was in an upper extremity lesion with
microscopic margins who received IR-192 HDR
brachytherapy. The dose schedule delivered 350cGy
to a 0.5-cm margin. This was delivered b.i.d. for
6days. Re-resection followed by multi-agent
chemotherapy has rendered this patient NED at 26
months. In this patient, the dose was delivered
to 0.5cm around the area marked with surgical clips
by the surgeon. A twice daily dose of 350cGy was
delivered for 6 days. In addition, each of these
three patients had received tamoxifen prior to
surgical intervention and irradiation. There was no
tumor response to this agent in any of these three
patients.
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A single patient experienced an unexpected grade
4 complication. In that patient soft tissue necrosis
developed following brachytherapy and external
beam irradiation. Review of the treatment plan
retrospectively did not demonstrate any unusual
dose in homogeneity or other factors that would
account for this problem. The remainder of
the patients had Grade I/Grade II skin reactions.
Two patients also reported, suffered from a
decrease in range of motion which improved with
an 85% of normal function following physical
therapy.
Discussion
Since 1994, there have been a number of published
reports that have dealt with the prognostic factors
and treatments for aggressive neurofibromatosis/
desmoid tumors. These series have reported on
various cohorts of patients who have included both
intra- and extra-abdominal desmoid lesions, primary
and recurrent disease and both adult and pediatric
patients.
1–6 However, there are several recurrent
themes to most of these series and they include the
importance of the status of the surgical margins,
whether treatment is in the initial postoperative
setting or is recurrent and the total dose of radiation
which is used.
The use of postoperative irradiation, in recurrent
setting, has reported 5-year local control rates
between 75 and 81% when irradiation is delivered,
while local failure rates as high as 100% were noted
when postoperative irradiation is omitted.
1–3,5,10
Our presented series has a similar local control rate
(76%) with a median follow-up of over 6 years.
Where we differ is in the fact that all sites had
surgical margins that we would consider to be
close or positive using the definition used by
Nuyttun in his meta analysis.
In that review, Nuyttens reviewed 22 series
published between 1983 and 1998.
4 Three sepa-
rate groups are identified in this review. They
included: (A) patients receiving surgery alone, (B)
those receiving surgery and irradiation, (C) those
receiving irradiation alone. Group A and B
patients were further subdivided by their surgical
margin status. These were then analyzed to
determine whether the treatment was based on
initial presentation, recurrent disease or unknown
tumor status. Local control for surgical patients
with negative surgical margins was 72%, for those
with positive margins it was 4%. Patients receiving
both surgery and irradiation enjoyed a local
control of 94% with negative surgical margins
and 75% for positive surgical margins. In all cases
use of irradiation þ/  surgery was superior in
establishing local control when compared to
surgery alone.
This meta analysis confirms the previous institu-
tional series and our presented data in which
about 75% of patients who receive postoperative
irradiation for positive surgical margins, as
defined in the meta analysis, enjoy local relapse-
free survival.
It is with this in mind that the randomized
report by Pisters et al. must be reviewed. In this
report there was no benefit to the use of brachy-
therapy in the treatment of low-grade sarcomas.
They report detailed doses of 42–45Gy being
delivered to the tumor bed in patients who had
no gross residual tumor, no violation of the tumor
during surgery and no involvement of major neuro-
vascular bundles. In addition, only those with
localized completely resected superficial trunk and
extremity sarcomas that resulted in limb salvage
were included.
It may be possible that this specific cohort of
patients (superficial low grade sarcomas that are
completely resected with negative margins) does not
need any further therapy and that the addition of
irradiation would not be beneficial in the overall
survival or local control, but could certainly enhance
complication rates. This paper, however, does not
deal with desmoid tumors and specifically it does not
report on recurrent lesions nor does it include
analysis of those with positive or close margins as
defined by Nuyttens in the meta analysis. Thus while
this paper is important in defining treatment options
for the described patient cohort, direct correlations
cannot be drawn as to the recommendations for
treatment in relapsed desmoids with close/positive
margins.
Our rationale for the use of brachytherapy was
that it might offer an opportunity to give a boost
to the primary tumor bed, and/or in selected
cases, in which it was used as monotherapy, may
have allowed for the advantage of a shortened
overall time to deliver therapy. However, as our
results demonstrated, the sole use of brachyther-
apy and specifically the use of Cf-252 did not
benefit the patients and our data suggest an
inferior rate of local control when brachytherapy
was used alone.
Complication rates in this group of patients were
similar to those reported in other series. These were
reported to range from 4 to 30% at different time
periods and also based on various doses. Nuttyens
reported an overall complication rate of 22%, with
the most frequent complication being fibrosis with
limited range of motion, occurring in about 9% of
patients. In our series only one patient had a
significant event (a soft tissue necrosis), which
healed with aggressive wound management. The
incidence of fibrosis/range of motion reduction was
three of 13 sites, including the site with the soft tissue
necrosis. In addition, to date no second malignant
neoplasm (SMN) has been diagnosed.
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For patients who present with desmoid tumors
and in whom resection results in a microscopic
residual margin or gross residual disease, the use of
postoperative radiation is not only warranted, but
critical in the ability to establish local control. We do
not advocate the use of brachytherapy alone, but it
may be used in combination with external beam
irradiation. To date no local failures have occurred
when total doses greater than 50Gy have been
utilized for microscopically positive margins and
56Gy for gross residual disease. Complication rates
in this special cohort of patients is acceptable, and to
date no second malignancies have been diagnosed.
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